1 tical analysis plan for the primary endpoint
was amended to a combined analysis of cohorts 1 and 2 (i
2 10, 2008, in response to new data, the trial
was amended to a prospectively stratified design, restri
3 observed declining event rate, the protocol
was amended to a time-based analysis.
4 mab induction group was closed and the study
was amended to a two-arm study.
5 The fluid mosaic model has recently
been amended to account for the existence of membrane do
6 On May 30, 2012, the study protocol
was amended to allow crossover from control to trastuzum
7 The protocol
was amended to allow patients in the investigator's choi
8 On Sept 12, 2012, the study protocol
was amended to allow patients with disease progression t
9 Subsequently, the protocol
was amended to assess OS by unadjusted log-rank test aft
10 ned enrollment of 252 patients, the protocol
was amended to continue with a three-arm design (1:1:6 r
11 Drug laws need to
be amended to ensure the safety and effectiveness of med
12 The study
was amended to exclude CR patients from receiving alemtu
13 The study protocol
was amended to exclude patients with prior hematopoietic
14 During the study the protocol
was amended to extend PR to 48 weeks for patients with p
15 As such, the method of administration
was amended to have a maximum infusion time of 60 minute
16 both R. dentocariosa and C. aurimucosum have
been amended to include charcoal-black-pigmented variant
17 For the trial ACOSOG Z1031B, the protocol
was amended to include a tumor Ki67 determination after
18 The protocol
was amended to include pegfilgrastim because of dose-lim
19 e-response correlation, the phase II portion
was amended to include several dose levels.
20 On April 6, 2011, the protocol
was amended to include three additional patients in the
21 additional toxicity was observed, the study
was amended to include two additional EOC + P dose level
22 The studies
were amended to include a joint analysis comparing group
23 pletion of the planned accrual, the protocol
was amended to introduce a third arm with rituximab alon
24 the fluency theory of aesthetic pleasure can
be amended to meet the requirements of the framework.
25 The study
was amended to reduce the starting dose of irinotecan to
26 Both studies
were amended to remove rituximab, but two of three addit
27 21 days for four cycles, until the protocol
was amended to six cycles.
28 FF formulations, PFASs, and ethylene glycols
were amended to the growth medium of a D. mccartyi-conta
29 The protocol then
was amended to treat the prostate volume first followed